Good MorningEquity markets tried to rebound on Wednesday but stumbled after getting what they wanted: soft labor data. While the ADP and JOLTs figures suggest softening in the labor market and may lead the FOMC to cut rates sooner than expected, there is a downside that should be considered. Slowing labor market growth and business spending will impact GDP in 2024 and may lead the economy into recession. The odds of a soft landing have grown in recent months, but investors should not be sanguine, the Fed has been behind the curve since the beginning of the inflation crisis and is unlikely to proactively cut rates. Cutting too soon will result in accelerating inflation and higher rates for longer.
The S&P 500 continues hovering at critical resistance with several potential catalysts. The first comes on Friday with the NFP report, expected to show a solid job gain of 190,000, the next is the following week and includes a double-shot of inflation news, the FOMC decisions and retail sales. The CPI and PPI will most likely confirm slowing inflation but the retail sales may also confirm weak spending and lackluster holiday season. Featured: Elon did what?! (Ad) 
|
Markets | |
Looking for consumer staples dividend stocks?
When investors are uncertain, they often look to consumer staples stocks since these companies sell things we can't go without, such as food, beverages and household products.
When inflation is high, investing in consumer staples stocks with dividen... Read the Full Story |
|
From Our Partners | | Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified a new venture quietly incubating inside Tesla. It has nothing to do with EVs, AI, or robotics, yet it generated $12 billion in 2025 alone.
Blackstone calls the broader opportunity a $23 trillion investment runway. Adam believes investors who position themselves before July 22 are early. He's also giving away a free ticker pick in his latest briefing. | | Watch Adam O'Dell's full briefing and get his free ticker now |
|
Markets | | Large, well-established, and financially stable businesses with a long history of reliable performance are often referred to as blue-chip companies. These companies are typically leaders in their industries and tend to have strong market positions, large market capitalizations, and robust financials... Read the Full Story |
|
Consumer Staples | |
When many investors first begin building an investment portfolio, they inadvertently veer toward the consumer staples sector. Consumer staples are companies that produce and sell essential products that people use daily, regardless of economic conditions. These companies tend to represent more sta... Read the Full Story |
|
From Our Partners | | Tom Busby calls them the '7 Sisters' - seven markets he checks before trading a single share each week: the S&P, Nasdaq, Dow, German DAX, gold, crude oil, and bonds.
With 45 years of trading experience, Busby delivers this full-board read every Monday before the open - covering key earnings, five stocks with exact support, resistance, and trigger levels, and the news that actually moves markets.
Built for stocks, options, and futures traders alike. | | See how Tom reads the 7 Sisters before the week opens |
|
Consumer Discretionary | |
If you're like most shoppers, you order many of the items you use daily online. In recent years, online shopping has evolved and adapted to people's needs, and very successful companies work exclusively online to address the specific needs of their consumers.
Savvy investors have noticed this tre... Read the Full Story |
|
Consumer Staples | |
When investing for dividends, a vital sequence is the ex dividend date vs record date. To be entitled to a company's dividend payout, an investor must hold shares through a specific day, which will vary depending on the company. Investors with long time horizons using "buy and hold" strategies don... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Finance | |
The commodity cycle is in full steam ahead mode, with one of the biggest markets (oil) taking the spotlight. Now that the Saudis have reiterated their commitment for OPEC to implement production cuts next year, which is a development that analysts at Goldman Sachs (NYSE: GS) are counting on to be ... Read the Full Story |
|
Retail/Wholesale | |
If there's one stock that's kept investors on their toes in recent years, it's Carvana Co (NYSE: CVNA). A 1,500% rally through August 2021 quickly turned into a 98% drop by the start of this year. Shares then rallied 1,500% again into September before dropping 55% at the start of last month. Do yo... Read the Full Story |
|
Technology | |
MongoDB’s (NASDAQ: MDB) share price fell about 5% following the Q3 release in what can only be a sell-the-news event. The company produced high double-digit growth that beat the consensus estimates and raised guidance, which should have been a catalyst for higher share prices. The problem fo... Read the Full Story |
|
Consumer Discretionary | |
In the ultra-competitive sneaker game, it’s Skechers U.S.A., Inc. (NYSE: SKX) 1, Nike 0.
Shares of the mid-cap footwear challenger are crushing those of its large-cap peer by a wide margin in 2023. Entering this week on a momentum-packed nine-day winning streak, Skechers stock is up 41% yea... Read the Full Story |
|
Retail/Wholesale | |
The stock market has been on a wild ride so far this year, with wild swings and emotional roller coasters. Don't you remember when everyone was scared of a recession once the FED began raising rates? And how about the banking crisis that took down a few institutions?
Now, the S&P 500 closed t... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. | | View Today's Stock Pick |
|
